Introduction
Carcinoembryonic antigen (CEA) is a well-established tumor marker associated with adenocarcinomas, and many monoclonal antibodies (MAbs) against CEA have been characterized since its discovery by Gold and Freedman in 1965 (1) . CEA is a member of a rather large family of glycoproteins found in a variety of normal and tumor tissues (2) . Measurement of circulating CEA by ELISA is a regular part of monitoring patients with colorectal cancer after tumor resection to help detect recurrences, and is also used to help determine response to chemotherapy and radiation therapy, Anti-CEA antibodies have utility for radioimmunodetection and radioimmunotherapy of colorectal cancer.
At present, the clinical applications of CEA detection in immunopathology are somewhat limited, in part because most of the available antibodies react nonspecifically with CEA-related antigens, particularly those found in normal colon mucosa and human granulocytes (3).
In this study, we describe the tissue reactivity of MAb COLI, which reacts with restricted CEA antigen epitopes (4) and which Supported in part by PHS Grant CA 52491 from the National Cancer Institute (SHI), and The Chemotherapy Foundation. SHI is recipient of an Irma T. Hirschl Career Scientist Award. 
Materials and Methods
Tissues. All specimens were formalin-flred, paraffin-embedded tissues obtained at surgical resection or biopsy. Normal colon tissues were obtained either from kidney donors immediately after accidental death or from patients undergoing surgery for non-neoplastic conditions. Remote colon mucosa came from histologically normal colon epithelium taken at least 6 un away from a colon cancer. Multiple tumor tissue sausage slides were a gift from Dr. Rodney T. Miller (Clarkson Hospital, Omaha, NB). Tissues were cut into sections 4-5 pm thick and mounted on poly-L-lysine-coated slides for immunostaining.
Reagens. MAb COLl was produced from mice immunized with a prep aration derived from membrane-enriched fractions of human colon carcinoma biopsy specimens (4). For comparison, a second anti-CEA MAb, clone number ZC-23, was also tested. The immunogen for MAb ZC-23 was CEA purified from a liver metastasis of colon adenocarcinoma. The Histostain-SP Kit and both MAbs are products of Zymed Laboratories (So. San Francisco, CA). The antibodies were used in a pre-diluted ready-to-use form. Capillaries in tissues (4) Heart (2)
Cardiovascular system
Number of cases tested in parentheses.
Muscular system Skeletal muscle (2)
Smooth muscle (15) Cardiac muscle (2) Urinary system Kidney ( 5 ) Bladder (3) Prostate (3) Testes (2) Breast (2) Uterus (1) Nervous system Cortex (2) Cerebellum (3) Peripheral nerve (2) Endocrine system Thyroid gland (3) Parathyroid ( with graded alcohols. Endogenous peroxidase activity was quenched by bathing slides in 3% H202 in methanol for 10 min at room temperature (RT). After rinsing with PBS, slides were treated with 10% normal rabbit serum anti-CEA MAb was applied to the slides and incubated at RT for io min, followed by incubations with a biotinylated antibody (rabbit anti-mouse) and with streptavidin-peroxidase, both for 10 min each at RT. Between incubations, the sections were washed 3 times in PBS for 2 min each. The sections were then treated with the chromogen aminoethylcarbazole (AEC), rinsed in tapwater, and immediately counterstained with hematoxylin and mounted with coverslips. Negative tissue control slides (tissue containing no CEA) and reagent control slides (using purified mouse IgG instead of anti-CEA MAb) were used for each immunohistostaining batch.
Results

Normal Tissues
We tested 35 different kinds of normal human tissues (Table 1) . None exhibited positive staining with MAb COLI.
Tumor Tissues
We tested 59 different kinds of human tumor tissues (Table 2) . Among these tumors, colorectal(47/52), gastric (17/20), and lung adenocarcinoma (313) showed the highest percentage of positive staining. COLl immunoreactivity occurred mostly on cell membranes and luminal contents of neoplastic glands (Figure 1 ). In addition, pancreatic (3/5), breast (3/10), gallbladder (3/4), bile duct (1/1), and bladder cancer (4/6) stained positive. One case of a malignant ovarian teratoma stained positive for COLl in areas with glandlike structures. One mucinous endometrial carcinoma was also positively stained. All other tumor types were negative for COLl immunoreactivity. 
Normal and Pre-dignant Colon Thsues
Because ofthe high sensitivity of COL1 immunodvity with colon cancers, we performed a more in-depth analysis of normal and premalignant colonic tissues (lible 3). None of the 20 specimens of normal colon mucosa reacted with COLI, and only 25% of colon mucosa specimens remote from a cancer w e n positive (Figures 2   and 3A) . In c o n u t , 90% of colon cancers were stained positivcly. Among these cases, all of the well-and moderately diffmntiated carcinomas, 70% ofthe poorly differentiated, and 58% of colloid carcinomas showed positive staining. In pre-malignant adenomatous polyps, the frequency of COL1 reactivity was greater in villous adenomas than in tubular adenomas. Table 4 compares CEA expression in colon tissues using MAb ZC-23 and MAb COLI. In contrast to MAb COLI, which did not react with normal mucosa ( Figure 3A ), 60% of normal colon tissues ( Figure 3B ) and 70% of specimens of remote mucosa stained positive with MAb ZC-23. Furthermore, ZC-23 reacted with neutrophils in the tissues, whereas these cells were not stained with COLl ( Figure 4) . MAbs COL1 and ZC-23 reacted with colon cancers with similar frequency.
Comparzson Between MAb COLI and MAb ZC-23
Discussion
Although efforts have been made to develop MAbs for CEA (6,7), the clinical application of CEA MAbs in pathology is still not widely accepted. This is due mainly to crossreactivity of these MAbs with CEA-related antigens, particularly NCA, in a large number of normal and benign human tissues. CEA belongs to a family of high molecular weight glycoproteins found in a variety of normal and malignant tissues. Other well-known members of this family include NCA, present in neutrophils and in some normal tissues such as colon, lung, and spleen (8), NCA-2 in meconium (9), NFA (normal fecal antigen) (lo), NFA-2 (ll), NFCA (normal fecal crossreacting antigen) (12) in normal adult feces, and BGP-1 (biliary glycoprotein-1) in normal bile (13) . CEA shares several common antigenic portions with these related antigens, i.e., NCA-homologous portions are shared with NCA, NCA-2, NFA-2, and NFCA. NFA-1-homologous portions are shared with NFA-1, NFA-2, and NCA-2. Finally, NFCA-homologous portions are shared with those of NFCA, NFA-2, and NCA-2 (14) .
A previous study has shown that MAb COL-1 does not react with . This suggests that COL1 might exhibit greater specificity for cancer tissues. Indeed, in the present study, all 35 ddferent normal human tissue sections, including normal colon, lung, spleen, and neutrophils, did not react with COL1. However, of the 59 different kinds of human tumor tissues tested, colorectal and gastric adenocarcinomas exhibited a high frequency of positive expression. This is in agreement with previous reports (4,16) suggesting CEA as a potentially useful tumor marker, at least for well-or moderately differentiated colon or gastric adenocarcinomas. Our results also showed that lung adenocarcinoma, but not small-cell or squamous carcinoma, stained positively with COLI, and this reagent may therefore be useful for distinguishing histological subtypes of lung cancer. Several other tumors, including pancreatic cancer, breast cancer, and bladder cancer, also manifested positive staining with COL1 in the present study. One case of ovarian teratoma displayed positive staining in glandular structures of the tumor, implying that this part probably has fetal gut origin. A beneficial feature of MAb COL1 is its lack of reactivity with normal colon tissues. The fact that 25% of remote colon mucosa at least 6 cm away from a cancer stained positively suggests that these areas represent pre-cancerous transformation. In addition, the greater frequency of COL1 reactivity in villous adenomas compared with tubular adenomas is also consistent with CEA expression correlating with malignant progression in the colon. In contrast, another MAb to CEA (ZC-23) was not specific for cancer detection.
Previous reports have shown that MAb COLl reacts with NCA-2 and NFA-2, although both of these antigens had a much lower affinity for COLl than CEA (15) . Since NCA-2 is present in meconium and NFA-2 is found in normal adult feces, this crossreactivity should not present a problem in applying COL1 in the differential diagnosis of colon neoplasms (9,ll).
The epitope recognized by MAb COG1 is resistant to periodate and neuraminidase, sensitive to pepsin, and partially resistant to heat, reduction alkylation, and pronase digestion (15) . These data, and the reactivity of COL1 with deglycosylated CEA (15), suggest that COL1 reacts with a peptide determinant on CEA.
In conclusion, MAb COL1 is an anti-CEA antibody that has minimal crossreactivity with other CEA-related antigens and therefore reacts only with certain cancers but not with normal tissues. These findings suggest that MAb COL1 may be a useful tool for immunopathological detection of neoplasms expressing CEA by immunohistochemistry, immunocytochemistry, and immunoassay, e.g., in helping to determine the origin of a metastatic tumor.
